Hormonal
Antihyperglycemic therapies reduce the risk of Major Adverse Cardiovascular Events (MACE) in a glycemic-dependent manner, where every 1% reduction in HbA1c is associated with a 14% relative reduction in MACE risk.
If you have type 2 diabetes, achieving a 1% reduction in your HbA1c through medication or lifestyle is associated with a 14% lower risk of major cardiovascular events like heart attack or stroke. This benefit is consistent across various drug classes, suggesting that effective glycemic control is a primary strategy for cardiovascular protection.
every 1% greater reduction in HbA1c was associated with a 14% reduction in the RR of MACE (95% CI 4–24; P = 0.010)
Why this rating
Based on a meta-analysis of 35 randomized controlled trials involving 256,524 patients, providing high statistical power and generalizability.
Source
Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials
Masashi Hasebe et al. · Cardiovascular Diabetology · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →